Operating Margin: 24.24%
Is the operating margin high or low?
The operating margin of 24.24% is 18% above its 5-year average of 20.52%, near the high end of its 5-year range (-7.53%–31.37%).
As of Sunday, June 28, 2026. 89.41% above its 12-month average of 12.80%.
TECH Operating Margin
Reported quarterly operating margin; no daily interpolation.
TECH Average Operating Margin Chart
TECH Current vs Average Operating Margin Chart
TECH Operating Margin Metrics
OPERATING MARGIN
24.24%
OPERATING MARGIN AVG TTM
12.80%
OPERATING MARGIN AVG 3Y
19.26%
OPERATING MARGIN AVG 5Y
21.92%
OPERATING MARGIN AVG 10Y
21.98%
OPERATING MARGIN AVG 15Y
27.68%
OPERATING MARGIN AVG 20Y
35.73%
CURRENT VS TTM AVG
+89.41%
CURRENT VS 3Y AVG
+25.88%
CURRENT VS 5Y AVG
+10.59%
CURRENT VS 10Y AVG
+10.30%
CURRENT VS 15Y AVG
-12.43%
CURRENT VS 20Y AVG
-32.15%
TECH Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 24.24% | 12.80% | 19.26% | 21.92% |
| Insulet Corp. (PODD)vs › | $10.96B | 17.48% | 16.20% | 12.06% | 10.90% |
| Baxter International Inc. (BAX)vs › | $11.38B | -2.65% | -1.31% | -6.02% | 0.15% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.39B | 11.77% | 9.13% | 12.39% | 13.51% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -2.02% | -7.24% | -2.92% | -1.15% |
| Molina Healthcare, Inc. (MOH)vs › | $11.97B | 1.16% | 2.96% | 3.72% | 4.01% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -18.13% | -59.22% | -59.52% | -72.58% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 5.60% | 5.75% | 6.18% | 6.20% |
| Revvity, Inc. (RVTY)vs › | $12.61B | 12.41% | 13.70% | 16.38% | 21.25% |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 14.44% | 15.23% | 16.08% | 17.45% |
Operating Efficiency
Gross Margin
65.0%
Operating Margin
24.2%
Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Operating Margin FAQ
- What is the operating margin for Bio-Techne Corporation (TECH)?
- The operating margin for TECH stock is 24.24%.
- Is Bio-Techne Corporation's operating margin high or low?
- The operating margin of 24.24% is 18% above its 5-year average of 20.52%, near the high end of its 5-year range (-7.53%–31.37%).
- What is the TTM average operating margin for Bio-Techne Corporation (TECH)?
- The TTM average operating margin for TECH stock is 12.80%.
- What is the 3Y average operating margin for Bio-Techne Corporation (TECH)?
- The 3Y average operating margin for TECH stock is 19.26%.
- What is the 5Y average operating margin for Bio-Techne Corporation (TECH)?
- The 5Y average operating margin for TECH stock is 21.92%.
- What is the 10Y average operating margin for Bio-Techne Corporation (TECH)?
- The 10Y average operating margin for TECH stock is 21.98%.
- What is the 15Y average operating margin for Bio-Techne Corporation (TECH)?
- The 15Y average operating margin for TECH stock is 27.68%.
- What is the 20Y average operating margin for Bio-Techne Corporation (TECH)?
- The 20Y average operating margin for TECH stock is 35.73%.
TECH Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2026-03-31 | 24.24% |
| 2025-12-31 | 18.41% |
| 2025-09-30 | 16.63% |
| 2025-06-30 | -7.53% |
| 2025-03-31 | 12.24% |
| 2024-12-31 | 15.96% |
| 2024-09-30 | 13.81% |
| 2024-06-30 | 14.97% |
| 2024-03-31 | 22.08% |
| 2023-12-31 | 13.94% |
| 2023-09-30 | 20.17% |
| 2023-06-30 | 31.37% |
| 2023-03-31 | 27.27% |
| 2022-12-31 | 25.00% |
| 2022-09-30 | 20.88% |
| 2022-06-30 | 27.95% |
| 2022-03-31 | 31.15% |
| 2021-12-31 | 23.15% |
| 2021-09-30 | 24.53% |
| 2021-06-30 | 26.48% |
| 2021-03-31 | 28.18% |
| 2020-12-31 | 22.74% |
| 2020-09-30 | 24.04% |
| 2020-06-30 | 22.36% |
| 2020-03-31 | 24.55% |
| 2019-12-31 | 20.00% |
| 2019-09-30 | 18.19% |
| 2019-06-30 | 22.57% |
| 2019-03-31 | 23.85% |
| 2018-12-31 | 19.26% |
| 2018-09-30 | 15.81% |
| 2018-06-30 | 23.81% |
| 2018-03-31 | 26.28% |
| 2017-12-31 | 15.66% |
| 2017-09-30 | 18.00% |
| 2017-06-30 | 26.49% |
| 2017-03-31 | 22.43% |
| 2016-12-31 | 12.25% |
| 2016-09-30 | 19.48% |
| 2016-06-30 | 29.69% |
| 2016-03-31 | 33.23% |
| 2015-12-31 | 29.80% |
| 2015-09-30 | 27.61% |
| 2015-06-30 | 32.13% |
| 2015-03-31 | 34.54% |
| 2014-12-31 | 30.89% |
| 2014-09-30 | 32.46% |
| 2014-06-30 | 41.99% |
| 2014-03-31 | 47.90% |
| 2013-12-31 | 42.54% |
| 2013-09-30 | 45.98% |
| 2013-06-30 | 50.10% |
| 2013-03-31 | 54.26% |
| 2012-12-31 | 49.15% |
| 2012-09-30 | 50.39% |
| 2012-06-30 | 52.39% |
| 2012-03-31 | 55.44% |
| 2011-12-31 | 50.47% |
| 2011-09-30 | 52.77% |
| 2011-06-30 | 54.59% |
| 2011-03-31 | 58.66% |
| 2010-12-31 | 55.16% |
| 2010-09-30 | 56.46% |
| 2010-06-30 | 58.35% |
| 2010-03-31 | 59.26% |
| 2009-12-31 | 55.79% |
| 2009-09-30 | 58.92% |
| 2009-06-30 | 56.15% |
| 2009-03-31 | 59.59% |
| 2008-12-31 | 52.78% |
| 2008-09-30 | 59.50% |
| 2008-06-30 | 57.25% |
| 2008-03-31 | 57.91% |
| 2007-12-31 | 52.95% |
| 2007-09-30 | 55.74% |
| 2007-06-30 | 55.58% |
| 2007-03-31 | 58.77% |
| 2006-12-31 | 52.40% |
| 2006-09-30 | 54.99% |
| 2006-06-30 | 55.14% |
| 2006-03-31 | 55.74% |
| 2005-12-31 | 50.57% |
| 2005-09-30 | 52.30% |
| 2005-06-30 | 56.33% |
| 2005-03-31 | 57.33% |
| 2004-12-31 | 52.29% |
| 2004-09-30 | 52.31% |
| 2004-06-30 | 52.47% |
| 2004-03-31 | 53.26% |
| 2003-12-31 | 48.23% |
| 2003-09-30 | 49.70% |
| 2003-06-30 | 48.34% |
| 2003-03-31 | 49.04% |
| 2002-12-31 | 43.74% |
| 2002-09-30 | 44.69% |
| 2002-06-30 | 40.89% |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman